Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis

Eur J Surg Oncol. 2015 Mar;41(3):282-94. doi: 10.1016/j.ejso.2014.11.039. Epub 2014 Nov 27.

Abstract

Several phase I/II studies of chemoradiotherapy for gastric cancer have reported promising results, but the significance of preoperative radiotherapy in addition to chemotherapy has not been proven. In this study, a systematic literature search was performed to capture survival and postoperative morbidity and mortality data in randomised clinical studies comparing preoperative (chemo)radiotherapy or chemotherapy versus surgery alone, or preoperative chemoradiotherapy versus chemotherapy for gastric and/or gastro-oesophageal junction (GOJ) cancer. Hazard ratios (HRs) for overall mortality were extracted from the original studies, individual patient data provided from the principal investigators of eligible studies or the earlier published meta-analysis. The incidences of postoperative morbidities and mortalities were also analysed. In total 18 studies were eligible and data were available from 14 of these. The meta-analysis on overall survival yielded HRs of 0.75 (95% CI 0.65-0.86, P < 0.001) for preoperative (chemo)radiotherapy and 0.83 (95% CI 0.67-1.01, P = 0.065) for preoperative chemotherapy when compared to surgery alone. Direct comparison between preoperative chemoradiotherapy and chemotherapy resulted in an HR of 0.71 (95% CI 0.45-1.12, P = 0.146). Combination of direct and adjusted indirect comparisons yielded an HR of 0.86 (95% CI 0.69-1.07, P = 0.171). No statistically significant differences were seen in the risk for postoperative morbidity or mortality between preoperative treatments and surgery alone, or preoperative (chemo)radiotherapy and chemotherapy. Preoperative (chemo)radiotherapy for gastric and GOJ cancer showed significant survival benefit over surgery alone. In comparisons between preoperative chemotherapy and (chemo)radiotherapy, there is a trend towards improved survival when adding radiotherapy, without increased postoperative morbidity or mortality.

Keywords: Adenocarcinoma; Gastro-oesophageal junction; Preoperative chemoradiotherapy; Preoperative chemotherapy; Stomach.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy*
  • Chemoradiotherapy, Adjuvant*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Esophagectomy*
  • Esophagogastric Junction / surgery*
  • Gastrectomy*
  • Humans
  • Neoadjuvant Therapy / methods
  • Radiotherapy, Adjuvant
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / therapy*
  • Treatment Outcome